Clinical Trials

Multiple Ascending Dose (MDX1105-01)

Location:

Trial status:

Inactive

Why is this study being done?

This is an open label, multicenter, dose escalation and multidose study of MDX-11-5, a fully human monoclonal IgG4 antibody targeting the Programed Death-Ligand 1 (PD-L1). The study will consist of 3 periods: Screening (up to 28 days), Treatment (up to 16 six-week cycles), and Follow-up (up to 6 months).

Last updated: 03/28/2013

NCT ID:

NCT00729664